TL;DR
This study investigates bronchial washing fluid (BWF) as a promising liquid biopsy alternative for genomic profiling in extensive-stage small cell lung cancer (ES-SCLC). BWF demonstrated high concordance with tumor tissue for detecting genomic alterations and TMB, offering a less invasive and potentially more sensitive option than plasma.
What Problem Does This Paper Address?
Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor survival rates. While new treatments are emerging, the clinical utility of genomic profiling is often hampered by the limitations of traditional tumor tissue biopsies. These limitations include invasiveness, difficulty in obtaining sufficient tissue, and the challenge of capturing tumor heterogeneity. Liquid biopsies, particularly those using plasma-derived cell-free DNA (cfDNA), have shown promise but can sometimes lack sensitivity or fail to capture the full genomic landscape. This study addresses the need for a more accessible and potentially more informative liquid biopsy method for SCLC by evaluating bronchial washing fluid (BWF) as a source of tumor DNA.
Methods
The researchers collected four types of samples from 21 ES-SCLC patients before chemotherapy: tumor tissue, BWF (separated into supernatant and precipitate), and plasma. Plasma was also collected post-chemotherapy. Next-generation sequencing (NGS) was performed on a 1021-gene panel to identify genomic alterations. The study focused on evaluating the concordance of genomic profiling results across these different sample types, comparing the detectability of somatic mutations, and assessing the correlation of tumor mutational burden (TMB) between BWF and tissue samples. They also analyzed clinical information for correlations with genomic findings.
Datasets
The study utilized samples from 21 extensive-stage small cell lung cancer (ES-SCLC) patients. The data collected included:
- 20 BWF supernatant (BWFs) samples
- 21 BWF precipitate (BWFp) samples
- 21 tumor tissue samples
- 20 pre-treatment plasma samples
- 13 post-treatment plasma samples
Key Insights and Ideas
- BWF as a viable liquid biopsy: The study strongly supports BWF as a valuable source for liquid biopsy in SCLC, showing high concordance with tumor tissue for detecting genomic alterations.
- BWFs outperform BWFp and plasma in sensitivity: The supernatant fraction of BWF (BWFs) demonstrated a higher mutation detection rate and allele frequency compared to the precipitate (BWFp) and pre-treatment plasma. This suggests that the cellular components in BWFp might dilute the tumor DNA signal.
- Complementary to tissue biopsy: BWF can detect mutations not found in tissue or plasma, highlighting its potential to provide a more comprehensive genomic picture.
- TMB correlation: Tumor mutational burden (TMB) measured in BWF (both BWFs and BWFp) and pre-treatment plasma strongly correlated with TMB from tumor tissue, suggesting BWF can be used to assess this important immunotherapy biomarker.
- Post-treatment plasma reflects treatment response: The decrease in mutation allele frequency (VAF) and mutant allele frequency (MVAF) in post-treatment plasma aligns with treatment response, indicating its utility for monitoring.
- Hyponatremia link to endocrine resistance: A pathway analysis revealed that the endocrine resistance pathway was enriched in patients with hyponatremia, suggesting a potential molecular mechanism for this common electrolyte imbalance in SCLC.
- Biochemical markers less sensitive: The study found that conventional biochemical tumor markers (ProGRP, NSE, CEA) had lower sensitivity for cancer detection compared to genomic sequencing of BWF.
Key Results
- High mutation detection: 100% of BWFs, BWFp, tumor tissues, and post-treatment plasma samples showed detectable somatic mutations. Only one pre-treatment plasma sample was negative for mutations.
- Concordance with tissue: For 19 patients with matched samples, 92.6% of alterations found in tissue were detected in BWFs, 85.5% in BWFp, and 79.9% in pre-treatment plasma.
- BWF detects more alterations than tissue alone: Across 19 patients, BWF samples (combined BWFs and BWFp) detected 213 alterations, exceeding the 204 found in tissue samples.
- Driver mutation concordance: Driver mutations showed high concordance: 100% in BWFs, 94.4% in BWFp, and 88.9% in pre-treatment plasma compared to tissue.
- TMB correlation: Strong correlations were observed between TMB in BWFs and tissue (r=0.9512), BWFp and tissue (r=0.9360), and pre-treatment plasma and tissue (r=0.8782).
- Post-treatment plasma shows reduced mutations: VAF and MVAF in post-treatment plasma were significantly lower than in pre-treatment plasma, consistent with treatment efficacy.
Limitations and Future Work
- Sample size: The study included 21 ES-SCLC patients, which is a relatively small cohort. The authors suggest that further studies with larger sample sizes are needed to confirm their findings.
- Clinical utility validation: While BWF shows promise, further restricted validation is needed before it can be widely adopted in routine clinical practice.
- Specificity of BWF for screening: The potential use of BWF sequencing for SCLC screening and adjuvant diagnosis needs further exploration to establish criteria and specificity.
- Prognostic value of mTBI: While lower mTBI in BWFs correlated with longer overall survival (OS), this finding requires confirmation in larger cohorts.
- Hyponatremia mechanism: The link between hyponatremia and the endocrine resistance pathway is an interesting observation that warrants further investigation to elucidate the molecular mechanisms.
- TMB and immunotherapy: The authors plan to further explore the correlation between TMB grade in BWF and first-line SCLC immunotherapy.
Summary updated